Jean-Philippe Bertocchio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4361158/publications.pdf

Version: 2024-02-01

23 papers 656 citations

758635 12 h-index 24 g-index

40 all docs

40 docs citations

times ranked

40

1051 citing authors

#	Article	IF	Citations
1	Sodium Bicarbonate Prescription and Extracellular Volume Increase: Realâ€world Data Results from the AlcalUN Study. Clinical Pharmacology and Therapeutics, 2022, 111, 252-262.	2.3	1
2	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Digestive and Liver Disease, 2022, 54, 309-315.	0.4	10
3	European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). European Journal of Endocrinology, 2022, 186, R33-R63.	1.9	73
4	A cytoskeletal function for PBRM1 reading methylated microtubules. Science Advances, 2021, 7, .	4.7	17
5	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers, 2021, 13, 6022.	1.7	14
6	Tubular Acidification Defect in Adults with Sickle Cell Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 16-24.	2.2	13
7	Red Blood Cell AE1/Band 3 Transports in Dominant Distal Renal Tubular Acidosis Patients. Kidney International Reports, 2020, 5, 348-357.	0.4	11
8	Hepatic Tumor Formation in Adult Mice Developmentally Exposed to Organotin. Environmental Health Perspectives, 2020, 128, 17010.	2.8	9
9	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell, 2020, 37, 720-734.e13.	7.7	74
10	Abstract 4815: Differential expression profiling of long noncoding RNA establishes UCA1 as a hallmark of renal medullary carcinoma. , 2020, , .		3
11	Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease. Kidney International, 2019, 96, 1020-1029.	2.6	32
12	Response to Letter to the Editor: "Pro-FHH: A Risk Equation to Facilitate the Diagnosis of Parathyroid-Related Hypercalcemia― Journal of Clinical Endocrinology and Metabolism, 2019, 104, 463-464.	1.8	0
13	Diagnosis and Management of Hyperparathyroidism. JAMA Internal Medicine, 2019, 179, 1732.	2.6	O
14	Pro-FHH: A Risk Equation to Facilitate the Diagnosis of Parathyroid-Related Hypercalcemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2534-2542.	1.8	34
15	Study of Metabolic Acidosis in Sickle Cell Disease Patients. Blood, 2018, 132, 3667-3667.	0.6	0
16	What is the significance of end-stage renal disease risk estimation in living kidney donors?. Transplant International, 2017, 30, 799-806.	0.8	6
17	Signification of distal urinary acidification defects in hypocitraturic patients. PLoS ONE, 2017, 12, e0177329.	1.1	5
18	Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A. PLoS ONE, 2016, 11, e0153635.	1.1	19

#	Article	IF	CITATIONS
19	Estimated or Measured GFR in Living Kidney Donors Work-up?. American Journal of Transplantation, 2016, 16, 3024-3032.	2.6	30
20	Familial Hypocalciuric Hypercalcemia Types 1 and 3 and Primary Hyperparathyroidism: Similarities and Differences. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2185-2195.	1.8	97
21	Modifications to bicarbonate conductivity: A way to increase phosphate removal during hemodialysis? Proof of concept. Hemodialysis International, 2016, 20, 601-609.	0.4	2
22	Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. Kidney International, 2016, 89, 354-362.	2.6	52
23	Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney International, 2011, 79, 1051-1060.	2.6	107